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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A71OA-pain intensity is strongly associated with loss of function and quality
of life. To date, it is unclear if NP alone, as a reﬂection of CS is associated
with los of (joint speciﬁc) function and quality of life in patients with hip
or knee OA. The primary aimof this study is therefore; to investigate if NP
is associated with loss of joint speciﬁc patient-centered functional out-
comes and Health Related Quality of life (HRQOL). The secondary aim is
to investigate the relationship between NP and centrally mediated
symptoms (mood, fatigue, sleep quality) and symptoms associated with
CS (widespread pain, illness burden, pain intensity at rest).
Methods: 299 adult primary OA-patients (139 hip-OA, 160 knee-OA)
completed a questionnaire survey bymail. The survey involved questions
about demographic characteristics, OA-pain duration, previous joint
surgery, widespread pain and comorbidities. Subsequently, themodiﬁed-
painDETECT questionnaire (mPDQ; to measure NP), the Knee or Hip
injury and Osteoarthritis Outcome Score (KOOS/HOOS; to measure joint
speciﬁc patient-centered functional outcomes), the Short Form-36 (SF-
36; to measure HRQOL), a joint pain Numeric Rating Scale, a Visual Ana-
logue Scale for joint pain at rest and the Pittsburgh Sleep Quality Index
were administered. Patients were grouped based on their mPDQ-score,
the ﬁrst group (n¼184) involved patients with a nociceptive pain phe-
notype (mPDQ score 12), the second group (n¼115) represented a
possible or likely neuropathic pain phenotype (mPDQ score >12).
Differences between groups were analyzed in case of continues varia-
bles by means of an independent samples t-test (non-parametric
equivalent in case of skewness). For non-continues data a Chi-square or
a Fisher’s exact test was used. A p-value of <0.05 is considered stat-
istically signiﬁcant.
Results: Ninety-two percent of the mPDQ-scores were non-zero and
38.5% of the total population corresponding to a possible or likely NP-
phenotype (hip-OA: 34.5%; knee-OA: 41.9%). The NP-group scored sig-
niﬁcantly higher on bodymass index (BMI), pain intensity, duration and
pain medication usage. None of the patients used non conventional
centrally acting pain medication. No signiﬁcant differences were
observed based on the presence of previous joint surgery. After
adjusting for relevant covariates like; sex, age, BMI, pain intensity and
pain duration: possible or likely NP was signiﬁcantly associated with
loss of joint speciﬁc outcomes on all 5 subscales of the KOOS/HOOS
(mean difference 9.8 points). This goes along with signiﬁcant loss of
HRQOL on the SF-36 dimensions “Physical Functioning” and “Bodily
Pain”. Furthermore, the NP phenotype was to a large extend sig-
niﬁcantly associated (adjusted for sex, age, BMI) with centrally medi-
ated symptoms (mood, p<0.05; fatigue, p<0.05; sleep quality, p¼0.062)
and features associated with CS (widespread pain, p<0.001; illness
burden, p<0.075; pain at rest, p<0.001).
Conclusions: The results indicate that NP -independent from pain
intensity and pain duration- is mainly associated with clinical relevant
loss of the physical (hip/knee speciﬁc) and functional aspects of HRQOL.
Due to the high prevalence of NP in OA-patients and the found asso-
ciation with centrally mediated symptoms and possible CS; it seems to
be justiﬁed to treat NP-patients more speciﬁcally with non-conven-
tional centrally acting pain medication.
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GENETIC VARIANTS IN THE SUPT3H-RUNX2 LOCUS CONFER
SUSCEPTIBILITY FOR BONE AND CARTILAGE RELATED DISORDERS
VIA LONG-RANGE REGULATION OF RUNX2
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Purpose: Genome-wide association studies (GWAS) have identiﬁed in
total 6 independent SNPs within the 5’ region of the RUNX2 gene to be
associated to cartilage and bone related phenotypes. We hypothesize
that these SNPs may regulate RUNX2 expression in a time- and differ-
entiation depended manner. In this way, these SNPs might regulate
cartilage and bone differentiation, which result in the multitude of
associations found in this region. Therefore we aim to elucidate the
effect of the identiﬁed SNPs on the regulation and expression of RUNX2
and how these confer susceptibility to cartilage and bone related dis-
orders, such as osteoarthritis and bone mineral density.
Methods: Independent GWAS signals were identiﬁed with linkage dis-
equilibrium (LD) data from the HapMap project and GCTA conditional
joint analysis. SNPs in LD with the GWAS loci were identiﬁed with the
SNAP tool and HaploReg (V2.2, Broad Institute). GWAS SNPs and SNPs inhigh LD were analyzed for enrichment in genomic regulatory regions,
and co-locationwithDNAbinding proteins using data from the ENCODE-
Project, Roadmap epigenetics project, Vista enhancer browser and the
FANTOM5database. In 96 chondrocytes fromexpanded human cartilage
samples for which GWAS-data was available, RUNX2-expression was
measured by RNA-sequencing, afterwhich eQTL analysis was performed
to determine the effect of the SNPs on gene expression. CTCF protein
binding was determined by ChIP-qPCR in human cartilage explants.
Results:Wehave identiﬁed7 SNPs in the5’regionof RUNX2 tobe robustly
associated to height (2 independent loci), bone mineral density (BMD),
osteoarthritis (OA, 2 independent loci),minimal joint spacewidth (mJSW)
and ossiﬁcation of the spine (OPPL) (see ﬁgure 1). Using LD data from the
GWAS signals we observed that 6 GWAS signals were independent of
another, but one of the signals formJSWwas inhigh LDwith that of hipOA
mJSW (r2 >0.8). Next we analysed all GWAS signals for enrichment in
genomic regulatory regions. All independent GWAS signals co-localized
to regions with enrichment of active enhancer markers, H3K4me1,
H3K27ac and DNase1 hypersensitivity enrichment and bi-directional
CAGE reads, in osteoblast and chondrogenic cells.
CTCF (CCCTC-binding factor or 11-zinc ﬁnger protein) is essential for
chromatin organization and gene regulation, its functions include tran-
scription initiationand the formationof long-rangechromatin interactions.
TheBMDassociated SNPswere situated in an area that is involved inCTCF-
binding in osteoablasts. These SNPs are located ~700 kb away from the
RUNX2 promoter, yet they do have a signiﬁcant effect (p<0.05) on RUNX2
gene expression in human cartilage (as quantiﬁed by RNAseq in 96 sam-
ples). In addition,weobservedthatwhenwestimulatedRUNX2expression
in human chondrocytes by TGFb stimulation, there is also an increase in
CTCF binding near the RUNX2 promoter. These results suggest that CTCF
binding may play a role in the regulation of RUNX2 gene expression.
Conclusions:We have shown that variants in the SUPT3H-RUNX2 locus
associated to cartilage and bone phenotypes are located in potential gene
regulatory regions, and effect RUNX2 gene expression. We hypothesize
that the SNPs are localized in long-range enhancers which, mediated by a
CTCF chromatin-loop to the RUNX2 promoters, regulate RUNX2 gene
expression in a time-and differentiation dependent manner during car-
tilage and bone development. Future studies will further investigate the
chromatin architecture of the SUPT3H-RUNX2 locus.
Figure 1. SNPs found in GWAS located in the SUPT3H-RUNX2 locus are
associated to bone and cartilage phenotypes.
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METHYLATION OF CARTILAGE DNA IS A MEDIATOR OF GENETIC RISK
AT SEVERAL OA SUSCEPTIBILITY LOCI
M.D. Rushton, L.N. Reynard, D.A. Young, C. Shepherd, R. Darlay,
H.J. Cordell, J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United
Kingdom
Purpose: Replicated OA genetic risk loci are now emerging through the
use of powerful case-control association studies. The analysis of the
epigenetics of OA has also received considerable attention in the last few
years, particularly CpG methylation in cartilage chondrocyte genomic
DNA. The vast majority of OA risk loci reported to date do not contain
amino-acid substitution polymorphisms that can account for the asso-
ciation signal, implying that OA risk alleles act by modulating gene
expression rather than by changing protein sequence. DNAmethylation
is a mechanism used by the cell to regulate gene expression and DNA
methylation is known to mediate genetic risk in several diseases
including rheumatoid arthritis. In this study we assessed whether DNA
methylation is an intermediary of OA genetic risk by correlating geno-
type at OA risk loci with cartilage DNA CpG methylation.
Methods: In the discovery analysis, DNAwas collected from the cartilage
of 110 elderly individuals. Seventy one of thesewere OA knee patients, 20
